{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:52:36Z","timestamp":1740142356665,"version":"3.37.3"},"reference-count":47,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100001843","name":"Department of Science and Technology- Science and Engineering Research Board (DST-SERB), Govt. of India","doi-asserted-by":"publisher","award":["YSS\/2015\/002035"],"award-info":[{"award-number":["YSS\/2015\/002035"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research (ICMR), Govt. of India","doi-asserted-by":"publisher","award":["2019-3458","ISRM\/11(54)\/2019"],"award-info":[{"award-number":["2019-3458","ISRM\/11(54)\/2019"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Breast cancer is one of the most commonly diagnosed cancer types among women worldwide. Cytochrome P450 aromatase (CYP19A1) is an enzyme in vertebrates that selectively catalyzes the biosynthesis of estrogens from androgenic precursors. Researchers have increasingly focused on developing non-steroidal aromatase inhibitors (NSAIs) for their potential clinical use, avoiding steroidal side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>The objective of the present work is to search for potential lead compounds from the ZINC database through various in silico approaches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In the present study, compounds from the ZINC database were initially screened through receptor independent-based pharmacophore virtual screening. These screened molecules were subjected to several assessments, such as Lipinski rule of 5, SMART filtration, ADME prediction using SwissADME and lead optimization. Molecular docking was further applied to study the interaction of the filtered compounds with the active site of aromatase. Finally, the obtained hit compounds, consequently represented to be ideal lead candidates, were escalated to the MD simulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The results indicated that the lead compounds might be potential anti-aromatase drug candidate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The findings provided a valuable approach in developing novel anti-aromatase inhibitors for the treatment of ER+ breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573409919666230112170025","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T09:02:02Z","timestamp":1673859722000},"page":"243-257","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring Potential Non-steroidal Aromatase Inhibitors for Therapeutic Application against Estrogen-dependent Breast Cancer"],"prefix":"10.2174","volume":"19","author":[{"given":"Khushboo","family":"Pandey","sequence":"first","affiliation":[{"name":"Bioinformatics Research Laboratory, Dr. D. Y. Patil Biotechnology &amp; Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, 411033, India"},{"name":"Genetics and Molecular Biology Research Laboratory, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, 411033, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6945-8288","authenticated-orcid":true,"given":"Kiran","family":"Bharat Lokhande","sequence":"additional","affiliation":[{"name":"Bioinformatics Research Laboratory, Dr. D. Y. Patil Biotechnology &amp; Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, 411033, India"},{"name":"Translational Bioinformatics and Computational Genomics Research Lab, Department of Life Sciences, Shiv Nadar Institution of Eminence, Gautam Buddha Nagar, UP, 201314, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-7719","authenticated-orcid":true,"given":"Achintya","family":"Saha","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Fine Chemical Technology, Rajabazar Science College, University of Calcutta, Machuabazar, Kolkata, West Bengal, 700009, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8573-4817","authenticated-orcid":true,"given":"Arvind","family":"Goja","sequence":"additional","affiliation":[{"name":"Genetics and Molecular Biology Research Laboratory, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, 411033, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-3042","authenticated-orcid":true,"given":"Kakumani Venkateswara","family":"Swamy","sequence":"additional","affiliation":[{"name":"Bioinformatics Research Laboratory, Dr. D. Y. Patil Biotechnology &amp; Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, 411033, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6271-4215","authenticated-orcid":true,"given":"Shuchi","family":"Nagar","sequence":"additional","affiliation":[{"name":"Bioinformatics Research Laboratory, Dr. D. Y. Patil Biotechnology &amp; Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, 411033, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"Siegel R.L.","year":"2017","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2017. CA Cancer J Clin 2017,67(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fonc.2017.00110","volume":"7","author":"Dall G.V.","year":"2017","unstructured":"Dall G.V.; Britt K.L.; Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front Oncol 2017,7,110","journal-title":"Front Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"DeSantis C.E.","year":"2019","unstructured":"DeSantis C.E.; Ma J.; Gaudet M.M.; Newman L.A.; Miller K.D.; Goding S.A.; Jemal A.; Siegel R.L.; Breast cancer statistics, 2019. CA Cancer J Clin 2019,69(6),438-451","journal-title":"CA Cancer J Clin"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1002\/cncr.32910","volume":"126","author":"Mutebi M.","year":"2020","unstructured":"Mutebi M.; Anderson B.O.; Duggan C.; Adebamowo C.; Agarwal G.; Ali Z.; Bird P.; Bourque J.M.; DeBoer R.; Gebrim L.H.; Masetti R.; Masood S.; Menon M.; Nakigudde G.; Ng\u2019ang\u2019a A.; Niyonzima N.; Rositch A.F.; Unger-Salda\u00f1a K.; Villarreal-Garza C.; Dvaladze A.; El Saghir N.S.; Gralow J.R.; Eniu A.; Breast cancer treatment: A phased approach to implementation. Cancer 2020,126(S10),2365-2378","journal-title":"Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.bjc.6604853","volume":"100","author":"Reeves G.K.","year":"2009","unstructured":"Reeves G.K.; Pirie K.; Green J.; Bull D.; Beral V.; Reproductive factors and specific histological types of breast cancer: Prospective study and meta-analysis. Br J Cancer 2009,100(3),538-544","journal-title":"Br J Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s10552-015-0670-9","volume":"26","author":"O\u2019Brien K.M.","year":"2015","unstructured":"O\u2019Brien K.M.; Sun J.; Sandler D.P.; DeRoo L.A.; Weinberg C.R.; Risk factors for young-onset invasive and in situ breast cancer. Cancer Causes Control 2015,26(12),1771-1778","journal-title":"Cancer Causes Control"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1002\/ijc.29968","volume":"138","author":"Sisti J.S.","year":"2016","unstructured":"Sisti J.S.; Collins L.C.; Beck A.H.; Tamimi R.M.; Rosner B.A.; Eliassen A.H.; Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses\u2019 health studies. Int J Cancer 2016,138(10),2346-2356","journal-title":"Int J Cancer"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","volume":"13","year":"2012","unstructured":"Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012,13(11),1141-1151","journal-title":"Lancet Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1210\/er.2004-0015","volume":"26","author":"Brueggemeier R.W.","year":"2005","unstructured":"Brueggemeier R.W.; Hackett J.C.; Diaz-Cruz E.S.; Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005,26(3),331-345","journal-title":"Endocr Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nature07614","volume":"457","author":"Ghosh D.","year":"2009","unstructured":"Ghosh D.; Griswold J.; Erman M.; Pangborn W.; Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009,457(7226),219-223","journal-title":"Nature"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"8464","DOI":"10.1021\/jm300930n","volume":"55","author":"Ghosh D.","year":"2012","unstructured":"Ghosh D.; Lo J.; Morton D.; Valette D.; Xi J.; Griswold J.; Hubbell S.; Egbuta C.; Jiang W.; An J.; Davies H.M.L.; Novel aromatase inhibitors by structure-guided design. J Med Chem 2012,55(19),8464-8476","journal-title":"J Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11154-007-9039-z","volume":"8","author":"Briest S.","year":"2007","unstructured":"Briest S.; Davidson N.E.; Aromatase inhibitors for breast cancer. Rev Endocr Metab Disord 2007,8(3),215-228","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0093-7754(03)00302-6","volume":"30","author":"Miller W.","year":"2003","unstructured":"Miller W.; Aromatase inhibitors: Mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003,30(4),3-11","journal-title":"Semin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1040-8428(86)80003-8","volume":"5","author":"Brodie A.M.H.","year":"1986","unstructured":"Brodie A.M.H.; Santen R.J.; Henderson I.C.; Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. Crit Rev Oncol Hematol 1986,5(4),361-396","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2011.02.018","volume":"340","author":"Miki Y.","year":"2011","unstructured":"Miki Y.; Abe K.; Suzuki S.; Suzuki T.; Sasano H.; Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 2011,340(2),168-174","journal-title":"Mol Cell Endocrinol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1477-7827-9-93","volume":"9","author":"de Ronde W.","year":"2011","unstructured":"de Ronde W.; de Jong F.H.; Aromatase inhibitors in men: Effects and therapeutic options. Reprod Biol Endocrinol 2011,9(1),93","journal-title":"Reprod Biol Endocrinol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"105950","DOI":"10.1016\/j.jsbmb.2021.105950","volume":"212","author":"Pires A.S.","year":"2021","unstructured":"Pires A.S.; Varela C.L.; Marques I.A.; Abrantes A.M.; Gon\u00e7alves C.; Rodrigues T.; Matafome P.; Botelho M.F.; Roleira F.M.F.; Tavares-da-Silva E.; Oxymestane, a cytostatic steroid derivative of exemestane with greater antitumor activity in nonestrogen-dependent cell lines. J Steroid Biochem Mol Biol 2021,212,105950","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1158\/1078-0432.CCR-04-2187","volume":"11","author":"Geisler J.","year":"2005","unstructured":"Geisler J.; L\u00f8nning P.E.; Aromatase inhibition: Translation into a successful therapeutic approach. Clin Cancer Res 2005,11(8),2809-2821","journal-title":"Clin Cancer Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1021\/jm060186y","volume":"49","author":"Gobbi S.","year":"2006","unstructured":"Gobbi S.; Cavalli A.; Rampa A.; Belluti F.; Piazzi L.; Paluszcak A.; Hartmann R.W.; Recanatini M.; Bisi A.; Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem 2006,49(15),4777-4780","journal-title":"J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1023\/A:1014490817731","volume":"19","author":"Pouget C.","year":"2002","unstructured":"Pouget C.; Fagnere C.; Basly J.P.; Besson A.E.; Champavier Y.; Habrioux G.; Chulia A.J.; Synthesis and aromatase inhibitory activity of flavanones. Pharm Res 2002,19(3),286-291","journal-title":"Pharm Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1021\/jm0508282","volume":"49","author":"Saberi M.R.","year":"2006","unstructured":"Saberi M.R.; Vinh T.K.; Yee S.W.; Griffiths B.J.N.; Evans P.J.; Simons C.; Potent CYP19 (Aromatase) 1-[(Benzofuran-2-yl)(phen ylmethyl)pyridine, -imidazole, and -triazole inhibitors: Synthesis and biological evaluation. J Med Chem 2006,49(3),1016-1022","journal-title":"J Med Chem"},{"key":"ref=22","first-page":"217","volume":"16","author":"Vinh T.K.","year":"2001","unstructured":"Vinh T.K.; Yee S.W.; Kirby A.J.; Nicholls P.J.; Simons C.; 1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: Synthesis and in vitro inhibition of human placental CYP19 aromatase. Anticancer Drug Des 2001,16(4-5),217-225","journal-title":"Anticancer Drug Des"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14756360400015256","volume":"20","author":"Saberi M.R.","year":"2005","unstructured":"Saberi M.R.; Shah K.; Simons C.; Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols: Synthesis and inhibition of P450 aromatase. J Enzyme Inhib Med Chem 2005,20(2),135-141","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0960-894X(99)00328-5","volume":"9","author":"Vinh T.K.","year":"1999","unstructured":"Vinh T.K.; Ahmadi M.; Lopez D.P.O.; Fernandez P.S.; Walters H.M.; Smith H.J.; Nicholls P.J.; Simons C.; 1-[(Benzofuran-2-yl)phenylmethyl]-triazoles and tetrazoles potent competitive inhibitors of aromatase. Bioorg Med Chem Lett 1999,9(14),2105-2108","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1016\/j.bmc.2005.07.038","volume":"13","author":"Su B.","year":"2005","unstructured":"Su B.; Hackett J.C.; D\u00edaz-Cruz E.S.; Kim Y.W.; Brueggemeier R.W.; Lead optimization of 7-benzyloxy 2-(4\u2032-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg Med Chem 2005,13(23),6571-6577","journal-title":"Bioorg Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1016\/j.bmc.2005.03.050","volume":"13","author":"Hackett J.C.","year":"2005","unstructured":"Hackett J.C.; Kim Y.W.; Su B.; Brueggemeier R.W.; Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem 2005,13(12),4063-4070","journal-title":"Bioorg Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1021\/jm0306024","volume":"47","author":"Kim Y.W.","year":"2004","unstructured":"Kim Y.W.; Hackett J.C.; Brueggemeier R.W.; Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem 2004,47(16),4032-4040","journal-title":"J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1021\/jm0492397","volume":"48","author":"Ulmschneider S.","year":"2005","unstructured":"Ulmschneider S.; M\u00fcller-Vieira U.; Klein C.D.; Antes I.; Lengauer T.; Hartmann R.W.; Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes\/-indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase. J Med Chem 2005,48(5),1563-1575","journal-title":"J Med Chem"},{"journal-title":"CATALYST 411 Users\u2019; Manual","year":"2005","key":"ref=29","unstructured":"CATALYST 411 Users\u2019; Manual Accelrys Software Inc2005"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.apsb.2011.04.003","volume":"1","author":"Zhao D.","year":"2011","unstructured":"Zhao D.; Wang H.; Lian Z.; Han D.; Jin X.; Pharmacophore modeling and virtual screening for the discovery of new fatty acid amide hydrolase inhibitors. Acta Pharm Sin B 2011,1(1),27-35","journal-title":"Acta Pharm Sin B"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2191-2858-2-7","volume":"2","author":"Pal M.","year":"2012","unstructured":"Pal M.; Paliwal S.; In silico identification of novel lead compounds with AT1 receptor antagonist activity: Successful application of chemical database screening protocol. Org Med Chem Lett 2012,2(1),7","journal-title":"Org Med Chem Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10822-015-9887-7","volume":"30","author":"Shahin R.","year":"2016","unstructured":"Shahin R.; Swellmeen L.; Shaheen O.; Aboalhaija N.; Habash M.; Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets. J Comput Aided Mol Des 2016,30(1),39-68","journal-title":"J Comput Aided Mol Des"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"Irwin J.J.","year":"2005","unstructured":"Irwin J.J.; Shoichet B.K.; ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005,45(1),177-182","journal-title":"J Chem Inf Model"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.csbj.2019.02.006","volume":"17","author":"Pal S.","year":"2019","unstructured":"Pal S.; Kumar V.; Kundu B.; Bhattacharya D.; Preethy N.; Reddy M.P.; Talukdar A.; Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase inhibitors. Comput Struct Biotechnol J 2019,17,291-310","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017,7(1),42717","journal-title":"Sci Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1023\/A:1007999920146","volume":"12","author":"B\u00f6hm H.J.","year":"1998","unstructured":"B\u00f6hm H.J.; Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol Des 1998,12(4),309-323","journal-title":"J Comput Aided Mol Des"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"103994","DOI":"10.1016\/j.dib.2019.103994","volume":"24","author":"Gandhi S.P.","year":"2019","unstructured":"Gandhi S.P.; Lokhande K.B.; Swamy V.K.; Nanda R.K.; Chitlange S.S.; Computational data of phytoconstituents from Hibiscus rosa-sinensis on various anti-obesity targets. Data Brief 2019,24,103994","journal-title":"Data Brief"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1145\/1188455.1188544","author":"Bowers K.","year":"2006","unstructured":"Bowers K.; Chow E.; Xu H.; Dror R.; Eastwood M.; Gregersen B.; Klepeis J.; Kolossv\u00e1ry I.; Moraes M.; Sacerdoti F.; Salmon J.; Shan Y.; Shaw D.; Molecular dynamics-scalable algorithms for molecular dynamics simulations on commodity clusters. SC'06. Proceedings of the ACM\/EEEI 2006,84","journal-title":"Proceedings of the ACM\/EEEI"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s11030-021-10334-z","volume":"26","author":"Lokhande K.B.","year":"2022","unstructured":"Lokhande K.B.; Ghosh P.; Nagar S.; Venkateswara S.K.; Novel B.; C-ring truncated deguelin derivatives reveals as potential inhibitors of cyclin D1 and cyclin E using molecular docking and molecular dynamic simulation. Mol Divers 2022,26(4),2295-2309","journal-title":"Mol Divers"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/00498254.2018.1482029","volume":"49","author":"Ozcan-Sezer S.","year":"2019","unstructured":"Ozcan-Sezer S.; Ince E.; Akdemir A.; Ceylan \u00d6.\u00d6.; Suzen S.; Gurer-Orhan H.; Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies. Xenobiotica 2019,49(5),549-556","journal-title":"Xenobiotica"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/jm015567k","volume":"45","author":"Cavalli A.","year":"2002","unstructured":"Cavalli A.; Recanatini M.; Looking for selectivity among cytochrome P450s inhibitors. J Med Chem 2002,45(2),251-254","journal-title":"J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1021\/ci050237k","volume":"46","author":"Schuster D.","year":"2006","unstructured":"Schuster D.; Laggner C.; Steindl T.M.; Palusczak A.; Hartmann R.W.; Langer T.; Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model 2006,46(3),1301-1311","journal-title":"J Chem Inf Model"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1021\/ci050026f","volume":"45","author":"Cross S.S.J.","year":"2005","unstructured":"Cross S.S.J.; Improved flexx docking using flexs-determined base fragment placement. J Chem Inf Model 2005,45(4),993-1001","journal-title":"J Chem Inf Model"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/jm800945c","volume":"52","author":"Neves M.A.C.","year":"2009","unstructured":"Neves M.A.C.; Dinis T.C.P.; Colombo G.; S\u00e1 e Melo M.L.; Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem 2009,52(1),143-150","journal-title":"J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/j.2042-7158.2010.01154.x","volume":"62","author":"Roy P.P.","year":"2010","unstructured":"Roy P.P.; Roy K.; Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives. J Pharm Pharmacol 2010,62(12),1717-1728","journal-title":"J Pharm Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/2105610","volume":"2017","author":"Rampogu S.","year":"2017","unstructured":"Rampogu S.; Son M.; Park C.; Kim H.H.; Suh J.K.; Lee K.W.; Sulfonanilide derivatives in identifying novel aromatase inhibitors by applying docking, virtual screening, and MD simulations studies. BioMed Res Int 2017,2017,1-17","journal-title":"BioMed Res Int"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409919666230112170025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212678\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409919666230112170025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:56:56Z","timestamp":1701719816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212678\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409919666230112170025","relation":{},"ISSN":["1573-4099"],"issn-type":[{"type":"print","value":"1573-4099"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}